Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 6/20 | 0.57 |
| ▸ | IGF1R | P08069 | 5/20 | 0.57 |
| ▸ | CDK7 | P50613 | 5/20 | 0.57 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.57 |
| ▸ | LCK | P06239 | 4/20 | 0.57 |
| ▸ | GSK3A | P49840 | 4/20 | 0.57 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.57 |
| ▸ | AURKA | O14965 | 4/20 | 0.57 |
| ▸ | ABL1 | P00519 | 4/20 | 0.57 |
| ▸ | RET | P07949 | 4/20 | 0.57 |
| ▸ | FLT3 | P36888 | 4/20 | 0.57 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.57 |
| ▸ | PRKAA1 | Q13131 | 4/20 | 0.57 |
| ▸ | PAK4 | O96013 | 3/20 | 0.57 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.57 |
| ▸ | FYN | P06241 | 3/20 | 0.57 |
| ▸ | CSF1R | P07333 | 3/20 | 0.57 |
| ▸ | MET | P08581 | 3/20 | 0.57 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.57 |
| ▸ | PIM1 | P11309 | 3/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2320462 | 0.93 | GSK3B (0.55) | GSK3BIGF1RCDK7AURKBLCK | |
| SCHEMBL2316257 | 0.91 | IGF1R (0.54) | GSK3BIGF1RCDK7AURKBLCK | |
| SCHEMBL2315154 | 0.88 | IGF1R (0.55) | GSK3BIGF1RCDK7AURKBLCK | |
| SCHEMBL2318578 | 0.87 | IGF1R (0.54) | GSK3BIGF1RCDK7AURKBLCK | |
| SCHEMBL2317582 | 0.87 | GSK3B (0.54) | GSK3BIGF1RCDK7AURKBLCK | |
| SCHEMBL2317147 | 0.87 | IGF1R (0.54) | GSK3BIGF1RCDK7AURKBLCK | |
| SCHEMBL2314851 | 0.86 | IGF1R (0.53) | GSK3BIGF1RCDK7AURKBLCK | |
| SCHEMBL1537040 | 0.86 | GSK3B (0.61) | GSK3BIGF1RCDK7AURKBLCK | |
| SCHEMBL2320278 | 0.83 | GSK3B (0.58) | GSK3BIGF1RCDK7AURKBLCK | |
| SCHEMBL1934805 | 0.83 | MTNR1A (0.51) | GSK3BIGF1RCDK7AURKBLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140349970-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2014-11-27 | — | — | US | claimed |
| US-20140349970-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140349970-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140349970-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-8785639-B2 | Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof | ABBVIE INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785639-B2 | Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof | ABBVIE INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785639-B2 | Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof | ABBVIE INC. (US) | 2014-07-22 | — | — | US | disclosed |
| EP-2506713-A1 | NOVEL TRICYCLIC COMPOUNDS | Abbott Laboratories (US) | 2012-10-10 | — | — | EP | disclosed |
| US-20110190489-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190489-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190489-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2011068899-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011068899-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349970-A1 | NOVEL TRICYCLIC COMPOUNDS | CCNI, IL2, IL4I1 | GSK3B 1274/4885IGF1R 295/4885CDK7 521/4885 |
| US-20110190489-A1 | Novel Tricyclic Compounds | CCNI, IL2, IL4I1 | GSK3B 1274/4885IGF1R 295/4885CDK7 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.